Table 1 Patient baseline demographics
|  | Overall (n = 80) | Residual (n = 53) | pCR (n = 27) | p value (corrected) |
|---|---|---|---|---|
Age, mean (SD) | 53.4 (10.2) | 54.2 (9.8) | 51.8 (11.1) | 0.2 |
Height, mean (SD) | 64.7 (2.4) | 64.7 (2.4) | 64.6 (2.5) | 0.42 |
Race, n (%) | ||||
 African American | 36 (45.0) | 22 (41.5) | 14 (51.9) | 0.04 |
 Asian | 2 (2.5) | 1 (1.9) | 1 (3.7) |  |
 Caucasian | 40 (50.0) | 29 (54.7) | 11 (40.7) |  |
 Hispanic | 1 (1.3) |  | 1 (3.7) |  |
 Missing | 1 (1.3) |  |  |  |
Histology, n (%) | ||||
 Invasive Ductal  Carcinoma | 72 (90.0) | 49 (92.5) | 23 (85.2) |  < 0.008 |
Invasive Lobular Carcinoma | 7 (8.8) | 4 (7.5) | 3 (11.1) | Â |
 Metaplastic Carcinoma | 1 (1.3) |  | 1 (3.7) |  |
Receptor status n (%) | ||||
 HR+/HER2+ | 24 (30.0) | 15 (28.3) | 9 (33.3) |  < 1 × 10–11 |
 HR+/HER2− | 28 (35.0) | 24 (45.3) | 4 (14.8) |  |
 HR−/HER2+ | 10 (12.5) | 6 (11.3) | 4 (14.8) |  |
 TNBC | 18 (22.5) | 8 (15.1) | 10 (37.0) |  |
Grade*, n (%) | ||||
 1 | 4 (5.0) | 4 (7.5) |  | 0.02 |
 2 | 27 (33.8) | 19 (35.8) | 8 (29.6) |  |
 2;3 | 4 (5.0) | 2 (3.8) | 2 (7.4) |  |
 3 | 42 (52.5) | 25 (47.2) | 17 (63.0) |  |
 Missing | 3 (3.8) | 3 (5.7) |  |  |
Tumor stage, n (%) | ||||
 T1 | 3 (3.8) | 2 (3.8) | 1 (3.7) |  < 1 × 10–3 |
 T2 | 57 (71.3) | 37 (69.8) | 20 (74.1) |  |
 T3 | 19 (23.8) | 13 (24.5) | 6 (22.2) |  |
 T4 | 1 (1.3) | 1 (1.9) |  |  |
Nodal stage, n (%) | ||||
 N0 | 24 (30.0) | 16 (30.2) | 8 (29.6) | 0.85 |
 N1 | 48 (60.0) | 32 (60.4) | 16 (59.3) |  |
 N2 | 8 (10.0) | 5 (9.4) | 3 (11.1) |  |
Regimen, n (%) | ||||
 AC-CFU | 1 (1.3) | 1 (1.9) |  |  < 1 × 10–8 |
 AC-T | 1 (1.3) |  | 1 (3.7) |  |
 ddAC-T | 9 (11.3) | 8 (15.1) | 1 (3.7) |  |
ddAC-wT | 22 (27.5) | 11 (20.8) | 11 (40.7) | Â |
 T | 1 (1.3) | 1 (1.9) |  |  |
 TC | 10 (12.5) | 9 (17) | 1 (3.7) |  |
 TCH | 2 (2.5) | 2 (3.8) |  |  |
 TCHP | 32 (40.0) | 19 (35.8) | 13 (48.1) |  |
 wT-ddAC | 1 (1.3) | 1 (1.9) |  |  |
 wTCarbo-ddAC | 1 (1.3) | 1 (1.9) |  |  |